Cargando…

A new paradigm for classifying and treating HER2‐positive breast cancer

BACKGROUND: Because of the phenomenal success of treatment with monoclonal antibodies and antibody‐drug conjugates targeting human epidermal growth factor receptor 2 (HER2), most patients with early‐stage HER2‐positive breast cancer (HER2+ BC) and some with limited metastatic diseases have been cure...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Xuexin, Yeung, Sai‐Ching J., Esteva, Francisco J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432420/ https://www.ncbi.nlm.nih.gov/pubmed/37254964 http://dx.doi.org/10.1002/cnr2.1841

Ejemplares similares

Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer
por: Morrow, Phuong Khanh H, et al.
Publicado: (2009)

The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer
por: Patel, Aena, et al.
Publicado: (2020)

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
por: de Oliveira Taveira, Mateus, et al.
Publicado: (2017)

HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development
por: Singh, J C, et al.
Publicado: (2014)

Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer
por: Gaibar, Maria, et al.
Publicado: (2020)

Targeting HER2 in breast cancer: new drugs and paradigms on the horizon
por: Tarantino, Paolo, et al.
Publicado: (2021)

Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells
por: Jin, Quanri, et al.
Publicado: (2010)

The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates
por: Escrivá-de-Romaní, Santiago, et al.
Publicado: (2023)

Targeting Androgen Receptor in Treating HER2 Positive Breast Cancer
por: He, Licai, et al.
Publicado: (2017)

HER2 therapy: Molecular mechanisms of trastuzumab resistance
por: Nahta, Rita, et al.
Publicado: (2006)

DUSP4 is associated with increased resistance against anti-HER2 therapy in breast cancer
por: Menyhart, Otília, et al.
Publicado: (2017)

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies
por: Esteva, Francisco J, et al.
Publicado: (2005)

The role of long non-coding RNA GAS5 in cancers
por: Ji, Jiali, et al.
Publicado: (2019)

Advances in treating HER2-positive breast cancer: an interview with Sunil Verma
por: Verma, Sunil
Publicado: (2014)

How we treat patients with metastatic HER2-positive breast cancer
por: Nader-Marta, G., et al.
Publicado: (2022)

Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm
por: Yang, Charlie, et al.
Publicado: (2023)

The TRAR gene classifier to predict response to neoadjuvant therapy in HER2‐positive and ER‐positive breast cancer patients: an explorative analysis from the NeoSphere trial
por: Triulzi, Tiziana, et al.
Publicado: (2021)

New Agents for the Management of Advanced HER2-Positive Breast Cancer
por: Royce, Melanie, et al.
Publicado: (2016)

Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy
por: Guiu, S., et al.
Publicado: (2013)

Pyrotinib Improves Survival in Previously Treated HER2-Positive Metastatic Breast Cancer
por: Jacobson, Anne
Publicado: (2022)

Immunotherapy for HER-2 positive breast cancer
por: Yang, Tingting, et al.
Publicado: (2023)

HER2/positive and HER2/low in inflammatory breast cancer recurrence
por: Movchan, Oleksii Volodimirovich, et al.
Publicado: (2022)

HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
por: Pernas, Sonia, et al.
Publicado: (2019)

STARD3: A New Biomarker in HER2-Positive Breast Cancer
por: Lodi, Massimo, et al.
Publicado: (2023)

Shifting Treatment Paradigms: Improvements in HR-Positive, HER-2- Negative Breast Cancer Care in Poland from a Clinical Perspective
por: Ziobro, Marek, et al.
Publicado: (2023)

Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
por: Al Rabadi, Luai S., et al.
Publicado: (2021)

The multigene classifiers 95GC/42GC/155GC for precision medicine in ER‐positive HER2‐negative early breast cancer
por: Naoi, Yasuto, et al.
Publicado: (2021)

Molecular mechanisms of resistance to HER2-targeted therapy
por: Esteva, FJ
Publicado: (2009)

Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib
por: Ulrich, Lara, et al.
Publicado: (2021)

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
por: Bon, Giulia, et al.
Publicado: (2020)

HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer
por: Hosonaga, Mari, et al.
Publicado: (2018)

Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
por: Stanowicka-Grada, Malwina, et al.
Publicado: (2023)

Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab
por: Duchnowska, Renata, et al.
Publicado: (2017)

Radiotherapy for HER 2 Positive Brain Metastases: Urgent Need for a Paradigm Shift
por: Ippolito, Edy, et al.
Publicado: (2022)

NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab
por: Bouwer, Nathalie I., et al.
Publicado: (2019)

Targeted therapy for HER2 positive breast cancer
por: Incorvati, Jason A, et al.
Publicado: (2013)

Educational Case: HER-2 Positive Breast Cancer
por: Jennings, Julia, et al.
Publicado: (2021)

Immunological Landscape of HER-2 Positive Breast Cancer
por: Moragon, Santiago, et al.
Publicado: (2022)

Immunotherapies against HER2-Positive Breast Cancer
por: Duro-Sánchez, Santiago, et al.
Publicado: (2023)

Prognostic and predictive role of spatially positioned tumour infiltrating lymphocytes in metastatic HER2 positive breast cancer treated with trastuzumab
por: Honkanen, Tiia J., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_r7j4pjp88p40q1v2ere6mrd17a